Parabolic Drugs is currently trading at its upper circuit limit of Rs. 4.45, up by 0.21 points or 4.95% from its previous closing of Rs. 4.24 on the BSE.
The scrip opened at Rs. 4.45 and has touched a high and low of Rs. 4.45 and Rs. 4.45 respectively. So far 2215 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 8.49 on 06-Jan-2014 and a 52 week low of Rs. 3.39 on 07-Aug-2013.
Last one week high and low of the scrip stood at Rs. 5.00 and Rs. 3.78 respectively. The current market cap of the company is Rs. 31.64 crore.
The promoters holding in the company stood at 38.02 % while Institutions and Non-Institutions held 18.88 % and 43.10 % respectively.
Credit rating agency, CARE has reaffirmed ‘D’ rating to Parabolic Drugs’ long term bank facilities worth Rs 696.60 crore which was enhanced from Rs 472.93 crore. The rating agency has also reaffirmed ‘D’ rating to the company’s short-term bank facilities worth Rs 108.68 crore which was reduced from Rs 317.68 crore. The rating continues to take into account the ongoing delays in debt servicing on account of the tight liquidity position of the company.
Parabolic Drugs (PDL) has commenced its commercial operations in 1998 with contract manufacturing of APIs and API intermediates for sales in India and abroad (including regulated markets). PDL presently has four facilities comprising of three manufacturing plants, viz, Derabassi and Chachrauli (both Punjab) and Panchkula and an R&D centre at Barwala (both Haryana).
